Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
NCT05678881
Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 25, 2022
Completion: Feb 23, 2024
NCT05429788
Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)
Start: May 18, 2022
Completion: Nov 8, 2022